Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C

• Status: Active, not recruiting
• Trial end date: 0000-00-00
• Target enrollment: 10
• Participant gender: Both

Summary

Study SPC3649-207E is designed as an extension study to the prior protocol to provide additional long-term safety and efficacy information for subjects participating in Study SPC3649-207.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Santaris Pharma A/S
• Treatments: Interferon-alpha; Interferons; Ribavirin
• Last Updated: 2014-11-17

Criteria

Inclusion Criteria:

• Participated in study SPC3649-207

Exclusion Criteria:

• Received investigational drug therapy after discontinuation, termination, or successful completion of study SPC3649-207